Streetbeat News

Earnings

BMRN

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced positive results from a Phase 2 study of VOXZOGO in children with hypochondroplasia, to be presented at the ACMG Annual Clinical Genetics Meeting. The study showed increased annualized growth velocity with no new safety concerns. Additionally, data from Phase 2 and 3 studies in achondroplasia demonstrated sustained growth improvement and quality of life benefits. BioMarin is also conducting a pivotal clinical trial program for VOXZOGO in hypochondroplasia and has ongoing extension studies in achondroplasia to fulfill post-marketing requirements.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:55 pm

PFE

Pfizer Inc (NYSE:PFE) announced positive results from a Phase 3 study of Adcetris combined with lenalidomide and rituximab for treating diffuse large B-cell lymphoma (DLBCL), showing significant improvement in overall survival compared to a placebo combination. This marks the third Phase 3 study where an Adcetris combination has shown an overall survival benefit in lymphoma treatment. The results are notable for evaluating heavily pre-treated patients. Pfizer acquired Adcetris through its $43 billion acquisition of Seagen Inc. PFE shares saw a slight decrease of 0.09% in premarket trading.

Portfolio Pulse from Vandana Singh

March 12, 2024 | 12:55 pm

AAL

American Airlines Group's stock is trading lower following the company's announcement of an increase in its Q1 average fuel price guidance.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:52 pm

AAWH

Ascend Wellness (OTCQX:AAWH) reported a Q4 revenue of $140.2 million, a 0.8% decrease QoQ but a 25% increase YoY, with a net loss of $19.3 million. The company's full-year revenue reached $519 million, up 28% from the previous year, driven by retail and wholesale business expansion. Adjusted EBITDA for Q4 was $32.4 million, up 9.6% QoQ and 14.8% YoY. The company generated $16.7 million in cash from operations and $8.4 million in free cash flow for the quarter. For the full year, Ascend Wellness generated $54.5 million in cash from operations and $30.3 million in free cash flow. Shares closed 10.92% lower at $1.06 per share.

Portfolio Pulse from Nina Zdinjak

March 12, 2024 | 12:51 pm

AAL

American Airlines Group has updated its Q1 average fuel price per gallon forecast to $2.80-$2.90, an increase from the previous forecast of $2.65-$2.85.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:51 pm

PACK

Ranpak Holdings' shares surged following the announcement of Q4 revenue results that exceeded expectations and the issuance of FY24 guidance. Additionally, Baird reaffirmed an Outperform rating on Ranpak's stock and increased the price target from $5 to $7.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:51 pm

BZ

Kanzhun shares surged following the announcement of impressive Q4 financial results, surpassing expectations. Additionally, the company has provided Q1 revenue guidance that exceeds analysts' forecasts and has announced a $200 million share buyback program.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:44 pm

ASML

CB

DIS

NTRA

On CNBC's 'Halftime Report Final Trades,' analysts highlighted Natera, Disney, ASML, and Chubb for their recent financial performances and strategic moves. Natera's strong guidance, Disney's profitability projection for Disney+, ASML's sales beat, and Chubb's solid fundamentals were key points. The companies' stock movements on Monday were also noted, with Natera and Disney seeing gains, ASML experiencing a decline, and Chubb also gaining.

Portfolio Pulse from Avi Kapoor

March 12, 2024 | 12:43 pm

ONON

ORCL

RGLS

Oracle (ORCL) shares rose by 14% following positive Q3 financial results. Regulus Therapeutics (RGLS) shares surged by 103% after announcing promising topline results from a Phase 1b study and a $100 million private placement. On Holding (ONON) shares fell by 18% due to disappointing Q4 financial results.

Portfolio Pulse from ryanfaloona@benzinga.com

March 12, 2024 | 12:43 pm

GUTS

Fractyl Health, Inc. (NASDAQ:GUTS) announced promising preclinical findings for RJVA-001, its first GLP-1 gene therapy candidate from the Rejuva platform, demonstrating potent and durable effects in treating obesity and type 2 diabetes compared to Semaglutide.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:40 pm